María José Pérez Lacasta

Dr. María José Pérez Lacasta


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
CVCelmira Laza Vásquez
Celmira Laza Vásquez
MHMaría José Hernández-Leal
María José Hernández-Leal
MCMisericòrdia Carles-Lavila
Misericòrdia Carles-Lavila
MLMaría José Pérez Lacasta
María José Pérez Lacasta
ICInés Cruz-Esteve
Inés Cruz-Esteve
OGon behalf of the DECIDO Group
on behalf of the DECIDO Group
This study explored the barriers and facilitators to the implementation of a risk-based breast cancer screening program from the point of view of Spanish health professionals. A cross-sectional study with 220 Spanish health professionals was designed. Data were collected in 2020 via a web-based survey and included the advantages and disadvantages of risk-based screening and barriers and facilitators for the implementation of the program. Descriptive statistics and Likert scale responses analyzed as category-ordered data were obtained. The risk-based screening was considered important or very important to reduce breast cancer mortality and promote a more proactive role for women in breast cancer prevention, to increase coverage for women under 50 years, to promote a breast cancer prevention strategy for women at high risk, and to increase efficiency and effectiveness. Switching to a risk-based program from an age-based program was rated as important or very important by 85% of participants. As barriers for implementation, risk communication, the workload of health professionals, and limited human and financial resources were mentioned. Despite the barriers, there is good acceptance, and it seems feasible, from the perspective of health professionals, to implement a risk-based breast cancer screening program in Spain. However, this poses a number of organizational and resource challenges.

31 July 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
NVNuria Vives
Nuria Vives
NTNoemie Travier
Noemie Travier
Albert FarreAlbert Farre
Albert Farre
GBGemma Binefa
Gemma Binefa
CLCarmen Vidal Lancis
Carmen Vidal Lancis
MGM-TICS Research Group
M-TICS Research Group
Background: Mobile phone–based SMS text message reminders have the potential to improve colorectal cancer screening participation rates. Objective: This study assessed the effectiveness and acceptability of adding targeted SMS text message reminders to the standard procedure for those who picked up but did not return their screening kit at the pharmacy within 14 days in a colorectal cancer screening program in Catalonia, Spain. Methods: We performed a randomized control trial among individuals who picked up a fecal immunochemical test (FIT) kit for colorectal cancer screening at the pharmacy but did not return it within 14 days. The intervention group (n=4563) received an SMS text message reminder on the 14th day of kit pick up and the control group (n=4806) received no reminder. A 30-day reminder letter was sent to both groups if necessary. The main primary outcome was the FIT completion rate within 30, 60, and 126 days from FIT kit pick up (intention-to-treat analysis). A telephone survey assessed the acceptability and appropriateness of the intervention. The cost-effectiveness of adding an SMS text message reminder to FIT completion was also performed. Results: The intervention group had higher FIT completion rates than the control group at 30 (64.2% vs 53.7%; P<.001), 60 (78.6% vs 72.0%; P<.001), and 126 (82.6% vs 77.7%; P<.001) days. Participation rates were higher in the intervention arm independent of sex, age, socioeconomic level, and previous screening behavior. A total of 339 (89.2%) interviewees considered it important and useful to receive SMS text message reminders for FIT completion and 355 (93.4%) preferred SMS text messages to postal letters. We observed a reduction of US $2.4 per participant gained in the intervention arm for invitation costs compared to the control arm. Conclusions: Adding an SMS text message reminder to the standard procedure significantly increased FIT kit return rates and was a cost-effective strategy. SMS text messages also proved to be an acceptable and appropriate communication channel for cancer screening programs. Trial Registration: ClinicalTrials.gov NCT04343950; https://www.clinicaltrials.gov/study/NCT04343950 International Registered Report Identifier (IRRID): RR2-10.1371/journal.pone.0245806

1 August 2021 in Patient Education and Counseling
Verified
Journal Article
Open access
MLMaría José Pérez Lacasta
María José Pérez Lacasta
MLMaría José Pérez Lacasta
María José Pérez Lacasta
Maria Feijoo-CidMaria Feijoo-Cid
Maria Feijoo-Cid
VRVanesa Ramos-García
Vanesa Ramos-García
MCMisericòrdia Carles-Lavila
Misericòrdia Carles-Lavila
To explore the barriers to and facilitators of healthcare professionals' implementation of SDM regarding screening programmes. A systematic review was conducted in PubMed, Cochrane Library, CINHAL, and PsyscInfo. The barriers and facilitators identified were classified into three factors based on their origin: patients, healthcare system performance, and healthcare professionals themselves. Eight studies were selected: seven related to cancer screening. The most significant facilitators were literacy and interest in active participation, both of which have their origins in patients. The most significant barriers identified for the first time in a systematic review were legal conflict, lack of remuneration and lack of flexibility in clinical guidelines in screening programmes. The results of this study show that there are differences between barriers and facilitators for SDM when it is applied in the context of healthy people who perform preventive activities, particularly screening, in contrast to general medical consultation contexts. The authors suggest that to advance in the practice of SDM, we need to develop and disseminate training documents. Further, SDM should be incorporated into clinical guidelines. There should be more studies focusing on healthcare professionals' behaviour within the context of the uncertainty of screening programmes.

12 September 2017 in Trials
Verified
Journal Article
Open access
PDF file
OGon behalf of the InforMa Group
on behalf of the InforMa Group
MCMisericòrdia Carles
Misericòrdia Carles
MMMontserrat Martínez-Alonso
Montserrat Martínez-Alonso
APAnna Pons
Anna Pons
MLMaría José Pérez Lacasta
María José Pérez Lacasta
MRMontserrat Rue
Montserrat Rue
The decision to participate or not in breast cancer screening is complex due to the trade-off between the expected benefit of breast cancer mortality reduction and the major harm of overdiagnosis. It seems ethically necessary to inform women so that they can actively participate in decision-making and make an informed choice based on their values and preferences. The objective of this study is to assess the effects of receiving information about the benefits and harms of screening on decision-making, in women approaching the age of invitation to mammography screening. A two-stage, randomized controlled trial (RCT). In the first stage, 40 Basic Health Areas (BHAs) will be selected and randomized to intervention or control. In the second stage, women within each BHA will be randomly selected (n = 400). Four breast cancer screening programs (BCSPs) of the Spanish public health system, three in Catalonia and one in the Canary Islands will participate in the study. Women in the intervention arm will receive a leaflet with detailed information on the benefits and harms of screening using mammography. Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial examinations of the BCSP. The primary outcome is informed choice, a dichotomous variable that combines knowledge, attitudes, and intentions. Secondary outcomes include decisional conflict; confidence in the decision made; anxiety about screening participation; worry about breast cancer; anticipated regret; time perspective; perceived importance of benefits/harms of screening; perceived risk of breast cancer; and leaflet acceptability. Primary and secondary outcomes are assessed 2–3 weeks after the intervention. This is the first RCT that assesses the effect of informing about the benefits and harms of breast cancer screening in Spain in women facing the decision to be screened using mammography. It aims to assess the impact of information on several decisional outcomes and to contribute to paving the road towards shared decision-making in breast cancer screening in our country. ClinicalTrials.gov registry, ID: NCT03046004 . Retrospectively registered on 4 February 2017. Trial name: InforMa study.

12 July 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JBJavier Bodoque-Cubas
Javier Bodoque-Cubas
JFJose Fernández-Sáez
Jose Fernández-Sáez
SMSergio Martinez-Hervas
Sergio Martinez-Hervas
MLMaría José Pérez Lacasta
María José Pérez Lacasta
MCMisericòrdia Carles-Lavila
Misericòrdia Carles-Lavila
STSantiago Tofé-Povedano
Santiago Tofé-Povedano
Objective: The increasing incidence of thyroid nodules (TNs) raises concerns about overdiagnosis and overtreatment. This study evaluates the clinical and economic impact of KOIOS, a Food and Drug Administration-approved artificial intelligence (AI) tool for the management of TN. Methods: A retrospective analysis was conducted on 176 patients who underwent thyroid surgery between May 2022 and November 2024. Ultrasound images were evaluated independently by an expert and novice operators using the American College of Radiology Thyroid Imaging Reporting and Data System, while KOIOS provided AI-adapted risk stratification. Sensitivity, specificity, and receiver operating (ROC) curve analysis were performed. The incremental cost-effectiveness ratio (ICER) was defined based on the number of optimal care interventions (fine-needle aspiration biopsies and thyroid surgeries). Both deterministic and probabilistic sensitivity analyses were conducted to evaluate model robustness. Results: KOIOS AI demonstrated similar diagnostic performance to the expert operator [area under the curve (AUC): 0.794, 95% confidence interval (CI): 0.718-0.871 vs 0.784, 95% CI: 0.706-0.861; P = .754] and significantly outperformed the novice operator (AUC: 0.619, 95% CI: 0.526-0.711; P < .001). ICER analysis estimated the cost per additional optimal care decision at −€8085.56, indicating KOIOS as a dominant and cost-saving strategy when considering a third-party payer perspective over a 1-year horizon. Deterministic sensitivity analysis identified surgical costs as the main drivers of variability, while probabilistic analysis consistently favored KOIOS as the optimal strategy. Conclusion: KOIOS AI is a cost-effective alternative, particularly in reducing overdiagnosis and overtreatment for benign TNs. Prospective, real-life studies are needed to validate these findings and explore long-term implications.

1 December 2010 in Revista Espanola de Salud Publica
Verified
Journal Article
Open access
PDF file
MLMaría José Pérez Lacasta
María José Pérez Lacasta
AGAleix Gregori Gomis
Aleix Gregori Gomis
MLMisericòrdia Carles Lavila
Misericòrdia Carles Lavila
RMRosa Gispert Magarolas
Rosa Gispert Magarolas
MAMontserrat Martínez Alonso
Montserrat Martínez Alonso
MMMontserrat Rué Monné
Montserrat Rué Monné
The decrease of breast cancer (BC) mortality rates has been attributed to early detection programs and therapeutic advances. The objective is to compare BC mortality trend in health regions of Catalonia during the period 1993-2007. In parallel, dissemination of periodic mammography in the health regions has been analyzed. Mortality and health surveys data were used. Poisson and «joinpoint» regression analyses were used to compare regional BC mortality rates and quantify their temporal evolution. Mixed effects models were used to compare the rates and their evolution by region. The BC mortality rate decreased 3% annually in Cataluña. Between 1993 and 2007, the standard mortality rate changed from 34.8 to 23.3 per 100,000 women. Barcelona ciutat showed higher mortality rates than the Centre (rate ratio (RR)=0.873), Costa de Ponent (RR=0.885), Tarragona (RR=0.9) and Lleida regions (RR=0.915), but these differences tend to disappear over time. There were no observed trend changes in the evolution of the regional mortality rates, except in the Centre region. The use of periodic mammography was similar across health regions. During the 90s, Barcelona ciutat had a 36.1% utilization of periodic mammography in women aged 40-74, in the 1994 survey, the Centre 23.7 and Costa de Ponent 25.2%. The progressive increase in the use of periodic mammography and the decrease of BC mortality were similar in the eight health regions of Catalonia.